{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:39:56Z","timestamp":1793687996120,"version":"4.5.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1097\/fpc.0000000000000219","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T09:11:54Z","timestamp":1458637914000},"page":"324-333","source":"Crossref","is-referenced-by-count":14,"title":["A genome-wide study of lipid response to fenofibrate in Caucasians"],"prefix":"10.1097","volume":"26","author":[{"given":"Marguerite R.","family":"Irvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Rotroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Aslibekyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Degui","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertha","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Motsinger-Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skylar","family":"Marvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Srinivasasainagendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Claas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Straka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Ordovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid B.","family":"Borecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Y.D.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome I.","family":"Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna K.","family":"Arnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210213","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"R2-2-20210213","first-page":"14B","article-title":"Plasma triglyceride as a risk factor for cardiovascular disease","volume":"14","author":"Austin","year":"1998","journal-title":"Can J Cardiol"},{"key":"R3-2-20210213","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","article-title":"Hypertriglyceridemia","volume":"19","author":"Pejic","year":"2006","journal-title":"J Am Board Fam Med"},{"key":"R4-2-20210213","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-2-20210213","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-2-20210213","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"R7-2-20210213","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/ATVBAHA.114.305172","article-title":"Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics","volume":"35","author":"Khetarpal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R8-2-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0381-2-1","article-title":"Database mining for selection of SNP markers useful in admixture mapping","volume":"2","author":"Baye","year":"2009","journal-title":"BioData Min"},{"key":"R9-2-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00156-4","article-title":"Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives","volume":"171","author":"Chapman","year":"2003","journal-title":"Atherosclerosis"},{"key":"R10-2-20210213","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2005.04.002","article-title":"Fibrates and coronary risk reduction","volume":"182","author":"Steiner","year":"2005","journal-title":"Atherosclerosis"},{"key":"R11-2-20210213","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11883-004-0104-8","article-title":"The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy","volume":"6","author":"Fazio","year":"2004","journal-title":"Curr Atheroscler Rep"},{"key":"R12-2-20210213","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.ATV.16.6.763","article-title":"Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia","volume":"16","author":"Guerin","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R13-2-20210213","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R14-2-20210213","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-2-20210213","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R16-2-20210213","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch Intern Med"},{"key":"R17-2-20210213","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOL.0b013e32833c1e74","article-title":"Fibrates: no ACCORD on their use in the treatment of dyslipidaemia","volume":"21","author":"Wierzbicki","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"R18-2-20210213","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/CIRCULATIONAHA.105.620450","article-title":"Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?","volume":"113","author":"Barter","year":"2006","journal-title":"Circulation"},{"key":"R19-2-20210213","doi-asserted-by":"crossref","first-page":"e48663","DOI":"10.1371\/journal.pone.0048663","article-title":"Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate","volume":"7","author":"Aslibekyan","year":"2012","journal-title":"PLoS ONE"},{"key":"R20-2-20210213","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FPC.0b013e328351a486","article-title":"Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study","volume":"22","author":"Irvin","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R21-2-20210213","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1194\/jlr.P001834","article-title":"Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study","volume":"51","author":"Wojczynski","year":"2010","journal-title":"J Lipid Res"},{"key":"R22-2-20210213","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc07-1687","article-title":"Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study","volume":"31","author":"Shen","year":"2008","journal-title":"Diabetes Care"},{"key":"R23-2-20210213","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/sj.ejhg.5202003","article-title":"The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment","volume":"16","author":"Smith","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"R24-2-20210213","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1161\/CIRCGENETICS.110.950667","article-title":"Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study","volume":"3","author":"Irvin","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"R25-2-20210213","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"R26-2-20210213","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R27-2-20210213","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10038-008-0302-2","article-title":"The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions","volume":"53","author":"Liu","year":"2008","journal-title":"J Hum Genet"},{"key":"R28-2-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FPC.0b013e32834fdd41","article-title":"A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network","volume":"22","author":"Aslibekyan","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R29-2-20210213","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.2354","article-title":"Fast and accurate genotype imputation in genome-wide association studies through pre-phasing","volume":"44","author":"Howie","year":"2012","journal-title":"Nat Genet"},{"key":"R30-2-20210213","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/bioinformatics\/btq559","article-title":"Robust relationship inference in genome-wide association studies","volume":"26","author":"Manichaikul","year":"2010","journal-title":"Bioinformatics"},{"key":"R31-2-20210213","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nmeth.1785","article-title":"A linear complexity phasing method for thousands of genomes","volume":"9","author":"Delaneau","year":"2012","journal-title":"Nat Methods"},{"key":"R32-2-20210213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nmeth.2307","article-title":"Improved whole-chromosome phasing for disease and population genetic studies","volume":"10","author":"Delaneau","year":"2013","journal-title":"Nat Methods"},{"key":"R33-2-20210213","doi-asserted-by":"crossref","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","article-title":"A flexible and accurate genotype imputation method for the next generation of genome-wide association studies","volume":"5","author":"Howie","year":"2009","journal-title":"PLoS Genet"},{"key":"R34-2-20210213","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"},{"key":"R35-2-20210213","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"R37-2-20210213","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat Genet"},{"key":"R38-2-20210213","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng.291","article-title":"Common variants at 30 loci contribute to polygenic dyslipidemia","volume":"41","author":"Kathiresan","year":"2009","journal-title":"Nat Genet"},{"key":"R39-2-20210213","doi-asserted-by":"crossref","first-page":"e51954","DOI":"10.1371\/journal.pone.0051954","article-title":"Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population","volume":"7","author":"Comuzzie","year":"2012","journal-title":"PLoS One"},{"key":"R40-2-20210213","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"},{"key":"R41-2-20210213","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/ATVBAHA.109.201020","article-title":"Genetic variants influencing circulating lipid levels and risk of coronary artery disease","volume":"30","author":"Waterworth","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R42-2-20210213","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.269","article-title":"Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts","volume":"41","author":"Aulchenko","year":"2009","journal-title":"Nat Genet"},{"key":"R43-2-20210213","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng.2926","article-title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk","volume":"46","author":"Holmen","year":"2014","journal-title":"Nat Genet"},{"key":"R44-2-20210213","doi-asserted-by":"crossref","first-page":"609","DOI":"10.33549\/physiolres.932341","article-title":"Impact of variants within seven candidate genes on statin treatment efficacy","volume":"61","author":"Vrablik","year":"2012","journal-title":"Physiol Res"},{"key":"R45-2-20210213","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"R46-2-20210213","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00018-009-8716-3","article-title":"Osteocrin \u2013 beyond just another bone protein?","volume":"66","author":"Moffatt","year":"2009","journal-title":"Cell Mol Life Sci"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T22:34:09Z","timestamp":1655332449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201607000-00002"}},"subtitle":["a combined analysis of the GOLDN and ACCORD studies"],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000219","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}